Steve M. Sabus

SVP & Chief Commercial Officer, Turning Point Therapeutics, Inc.

Companies

Syndax Pharmaceuticals IncChief Commercial Officer Dec 5, 2022 to Dec 5, 2022¹
Turning Point Therapeutics, Inc.SVP & Chief Commercial Officer Jun 1, 2022 to Aug 17, 2022²

Holdings

Stock this person has reported owning, from the forms officers and directors file with the SEC. See the biggest insider stakes.

Shares held

Turning Point Therapeutics, Inc.0 shares³Aug 17, 2022

As of each latest filing. The line shows shares held over time.

Recent filings

Aug 17, 2022Returned to company 36,667 shares at $76.00 of Turning Point Therapeutics, Inc.³
May 31, 2022Granted 36,667 shares of Turning Point Therapeutics, Inc.⁴

Sources

The numbers on this page point here. Each one links to the record it came from.

1
SEC EDGARSyndax Pharmaceuticals Inc, Chief Commercial Officer
2
SEC EDGARTurning Point Therapeutics, Inc., SVP & Chief Commercial Officer
3
SEC EDGARTurning Point Therapeutics, Inc. shares after the filing of Aug 17, 2022
4
SEC EDGARForm 4 filed Jun 1, 2022